AbbVie (ABBV) 10-K Summaries & Annual Filing History
Review AbbVie Inc. (ABBV) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
AbbVie reported higher annual revenue and operating cash flow, with net income at reported level and major investing outflows tied to acquisitions. Risks remain from litigation, acquisition integration, and cybersecurity threats.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$61.2B
Revenue reported for the fiscal year.
Operating income
$15.1B
Income from operations reported for the year.
Net income
$4.2B
Net income reported for the year.
Operating cash flow
$19B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $58.1B | +3.3% |
| Dec 31, 2023 | $54.3B | -6.4% |
| Dec 31, 2024 | $56.3B | +3.7% |
| Dec 31, 2025 | $61.2B | +8.6% |
Business overview
AbbVie is a biopharmaceutical company that discovers, develops, and markets therapies across several therapeutic areas. The filing references research and development, commercial operations, and manufacturing activities as core to its business model.
Financial performance
Revenue increased compared to the prior year, with operating income and net income at the levels reported. Operating cash flow also rose, driven by higher net revenues and lower acquisition-related cash expenses, partially offset by litigation payments and contingent consideration.
Material risks
Stated risks include potential adverse outcomes from litigation matters, the uncertainties of integrating acquired businesses like ImmunoGen and Cerevel Therapeutics, and cybersecurity vulnerabilities. The filing also notes that litigation-related payments impacted cash flow.
Liquidity and capital
The company generated strong operating cash flow, which it used to fund acquisitions, capital expenditures, and debt repayments. In the reported period, it issued senior notes and used a term loan, while also repaying maturing senior notes.
What to watch
Monetize whether the trends in operating cash flow are sustained, particularly as litigation payments and contingent consideration liabilities evolve.